Lifecore Biomedical, Inc. Common Stock (LFCR)

Price$4.85

Value ScoreC

Growth ScoreD

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-47.82%

Price vs S&P 500 (4W)-9.53%

VGM Score36.87

Market Capitalization$183.80M

All Metrics

P/CF (Annual)25.07x

Book Value / Share (Quarterly)$0.55

P/TBV (Annual)5.76x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-9.91%

Cash Flow / Share (Quarterly)$0.28

Price vs S&P 500 (YTD)-49.56%

Gross Margin (TTM)30.03%

Net Profit Margin (TTM)-26.51%

EPS (TTM)$-1.18

10-Day Avg Trading Volume0.19M

EPS Excl Extra (TTM)$-1.18

Revenue Growth (5Y)-15.13%

EPS (Annual)$-0.48

ROI (Annual)-10.19%

Gross Margin (Annual)31.37%

Net Profit Margin (5Y Avg)-40.52%

Cash / Share (Quarterly)$0.55

Revenue Growth QoQ (YoY)-34.02%

ROA (Last FY)-7.74%

Revenue Growth TTM (YoY)27.59%

EBITD / Share (TTM)$0.18

ROE (5Y Avg)-104.45%

Operating Margin (TTM)-1.89%

Cash Flow / Share (Annual)$0.10

P/B Ratio8.85x

P/B Ratio (Quarterly)6.71x

Net Income / Employee (Annual)$-47,000

EV / Revenue (TTM)1.87x

Net Interest Coverage (TTM)-0.13x

ROA (TTM)-18.91%

EV / EBITDA (TTM)47.09x

EPS Incl Extra (Annual)$-0.48

Current Ratio (Annual)3.49x

Quick Ratio (Quarterly)2.33x

3-Month Avg Trading Volume0.27M

52-Week Price Return-26.72%

EV / Free Cash Flow (Annual)85.78x

Revenue / Employee (TTM)$435,300

Tangible BV / Share (Quarterly)$0.87

P/S Ratio (Annual)2.43x

Asset Turnover (Annual)0.33x

52-Week High$8.98

Operating Margin (5Y Avg)-19.38%

EPS Excl Extra (Annual)$-0.48

CapEx CAGR (5Y)-31.08%

Tangible BV CAGR (5Y)-35.73%

26-Week Price Return-31.89%

Quick Ratio (Annual)2.18x

13-Week Price Return-31.89%

Total Debt / Equity (Annual)4.18x

Current Ratio (Quarterly)3.79x

Enterprise Value$311.74M

Revenue / Share Growth (5Y)-19.16%

Asset Turnover (TTM)0.71x

Book Value / Share Growth (5Y)-32.61%

Revenue / Employee (Annual)$197,700

Inventory Turnover (Annual)2.45x

Pretax Margin (Annual)-23.34%

Cash / Share (Annual)$0.47

3-Month Return Std Dev84.89%

Gross Margin (5Y Avg)29.90%

Net Income / Employee (TTM)$-115,400

EBITDA CAGR (5Y)-23.76%

EBITDA Interim CAGR (5Y)-34.51%

ROE (Last FY)-52.73%

Net Interest Coverage (Annual)-0.25x

EPS Basic Excl Extra (Annual)$-0.48

P/FCF (TTM)17.56x

Receivables Turnover (TTM)5.49x

EV / Free Cash Flow (TTM)29.79x

Total Debt / Equity (Quarterly)7.16x

EPS Incl Extra (TTM)$-1.18

Receivables Turnover (Annual)3.86x

ROI (TTM)-25.44%

P/S Ratio (TTM)1.11x

Pretax Margin (5Y Avg)-29.05%

Revenue / Share (Annual)$2.02

Tangible BV / Share (Annual)$1.17

Price vs S&P 500 (52W)-54.92%

Year-to-Date Return-38.63%

5-Day Price Return1.83%

EPS Normalized (Annual)$-0.48

ROA (5Y Avg)-19.95%

Net Profit Margin (Annual)-23.78%

Month-to-Date Return-0.99%

Cash Flow / Share (TTM)$-1.85

EBITD / Share (Annual)$0.13

Operating Margin (Annual)-0.97%

LT Debt / Equity (Annual)3.98x

P/CF (TTM)10.58x

ROI (5Y Avg)-29.14%

LT Debt / Equity (Quarterly)7.11x

EPS Basic Excl Extra (TTM)$-1.18

P/TBV (Quarterly)8.46x

P/B Ratio (Annual)9.00x

Inventory Turnover (TTM)3.71x

Pretax Margin (TTM)-26.06%

Book Value / Share (Annual)$0.91

Price vs S&P 500 (13W)-41.63%

Beta1.11x

P/FCF (Annual)50.58x

Revenue / Share (TTM)$4.44

ROE (TTM)-126.79%

52-Week Low$3.63

vGradeC

gGradeD

mGradeD

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.43est. -0.24

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

3.91

4.09

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
LFCRLifecore Biomedical, Inc. Common Stock	C	D	D	$4.85
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
ABTAbbott Laboratories	C	C	D	$87.78
PFEPfizer Inc.	B	C	C	$25.63
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Lifecore Biomedical is a fully integrated CDMO providing development, manufacturing, and fill-finish services for complex sterile injectable pharmaceuticals. The company serves multiple delivery formats—syringes, vials, and cartridges—and operates two business segments: contract development and manufacturing services, and hyaluronic acid manufacturing.